

Ltr 17 October 03 National Tender

Highly Confidential: NOT FOR DISCLOSURE



Skipton House
80 London Road
London SE1 6LH
Tel: 020 7972 3764
Fax: 020 7972 5714

e-mail: richard.gutowski@dh.gov.uk

GRO-C

To: Members of the Recombinant Clotting
Factors Working Group

17 October 2003

Dear Member

Roll-out of Recombinant Clotting Factors

I attach the suggested plan for awarding the national tender and I would be grateful for your urgent endorsement by Friday 24 October so that PASA can place the contracts. I would at this stage like to place on record my thanks to Frank Hill and Charles Hay for the work they have put in getting to this stage.

It is important to note a few things in considering the plan. Firstly the underspend in all the years which needs to be looked at in the context of treatment for inhibitor patients and the need also for further work on the funding of such patients and funding for FV11. As agreed at our last meeting I would like to set up a small sub-group to look at this area and would like to invite nominations.

The reasons for this underspend are that in year 2, if we consider including patients aged 42, it results in an overspend and the spend in year 1 has to match the spend in year 2. We may need to adjust the spend when we roll out eg the model usage/patient may now be greater than the year in which the data was collected. If we can find a way of holding stock with the surplus that remains in year 1, then we can use this together with the underspend in year 2 to roll out to more patients in year 3. Again I suggest a small sub-group is convened to look at this issue of stock holding and stock management to use up the underspends in the budgets and I would welcome nominations.

We also need to offer advice to Centre Directors and Chief Executives as to how the roll out will work in practice. I volunteer to Chair this working group and would welcome other nominations.

I hope you all agree that we need PASA to place the contracts immediately even if it is on the basis of minimum usage for these years. The way it is currently set out hopefully maximises the benefits from competitive pricing in the tender whilst allowing physicians choice in selecting the products.

Yours sincerely

R M GUTOWSKI
Blood Policy Team